Sanofi highlighted its Dupixent life-cycle management (LCM) strategy with a subtle pivot ahead of a new CEO's arrival.1
Dupixent sales reached nearly €4.2 billion in Q1 2026, driving Sanofi to beat sales and profit forecasts and raise its 2030 sales target to about $30 billion.25
Sanofi plans a 'vigorous defense' to extend Dupixent's patent protection beyond 2031 amid looming loss of exclusivity (LOE) risks in the early 2030s.3
Dupixent received US approval on April 22, 2026, as the first biologic for young children (aged 2-11) with uncontrolled chronic spontaneous urticaria (CSU), following a positive EU CHMP opinion on February 27, 2026.47
Sanofi's potential Dupixent successor, amlitelimab, showed mixed Phase III results in atopic dermatitis but is advancing toward regulatory approval with a differentiated quarterly dosing profile.6
Sources:
1. https://firstwordpharma.com/story/7205595
2. https://finimize.com/content/sanofi-beat-estimates-but-dupixent-still-does-the-heavy-lifting
3. https://www.fiercepharma.com/pharma/sanofi-expects-extend-its-loe-dupixent-beyond-2031
4. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-27-12-03-24-3246438
5. https://www.investing.com/news/transcripts/earnings-call-transcript-sanofis-q1-2026-earnings-beat-forecasts-stock-rises-93CH-4632382
6. https://www.clinicaltrialsarena.com/news/sanofi-amlitelimab-phase-iii-coast2-shore-atopic-dermatitis/